CLYM
Climb Bio, Inc.
There isn't enough reported data to score CLYM yet.
CLYM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
CLYM's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
CLYM PE Valuation
CLYM has no meaningful PE right now: it lost money over the past year.
CLYM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect CLYM's earnings, revenue and profitability to hold roughly steady. However, they disagree widely on these estimates.
CLYM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$2.12 | -$0.65 |
| Q2 2024 | -$2.14 | -$0.45 |
| Q1 2024 | -$0.52 | +$1.54 |
| Q4 2023 | -$1.30 | +$0.42 |
CLYM is still losing money, but far less than before: $0.81 per share over the past year, against $6.77 at its worst in late 2021.
CLYM Quarterly Revenue
CLYM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$12.8M | -$572K |
| Q1 2026 | -$14.4M | +$1.1M |
| Q4 2025 | -$15.6M | -$10.1M |
| Q3 2025 | -$12.2M | -$4.7M |
| Q1 2025 | -$15.4M | -$13.6M |
| Q4 2024 | -$5.5M | -$4.6M |
| Q3 2024 | -$7.6M | -316% |
| Q1 2024 | -$1.8M | +$13.4M |
CLYM has burned cash in almost every quarter: −$55M over the past year, against −$30M the year before.
CLYM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +3.9M shares |
| 1 year | +18% | +12.4M shares |
| 3 years | +202% | +53.5M shares |
| 5 years | +586% | +68.4M shares |
CLYM has 80M diluted shares, up 18% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CLYM Net Leverage
CLYM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CLYM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.0 | Neutral |
| Stochastic | 19.6 | Oversold |
CLYM's weekly RSI is 48 (neutral) and its Stochastic is 20 (oversold).
CLYM PE vs Healthcare Sector
CLYM has no meaningful PE right now: it lost money over the past year.
CLYM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.6 | 2.3% above |
| 20 week MA | $12.8 | 15% below |
| 50 week MA | $9.52 | 14% above |
| 100 week MA | $5.59 | 94% above |
| 200 week MA | $4.82 | 126% above |
CLYM's trend is mixed: it's above four of its five weekly moving averages, and 126% above its 200-week average.
CLYM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $14.5 | $14.2 | -1.8% |
| 2022 | $14.2 | $2.93 | -79% |
| 2023 | $2.93 | $2.70 | -7.8% |
| 2024 | $2.70 | $2.10 | -22% |
| 2025 | $2.10 | $4.93 | +135% |
| 2026 YTD | $4.93 | $10.9 | +120% |
CLYM's yearly returns have swung widely, from +135% in 2025 to −79% in 2022. It's up 120% so far in 2026.